Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXN PR versus OxyPR for osteoarthritis pain with opioid-induced constipation
NL-OMON33756Phase 3Active, not recruiting
- Sponsor
- Mundipharma
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oxycodone + naloxone and oxycodone in osteoarthritis (OA) (2 arms), sponsored by Mundipharma. Primary endpoints: Analgesic efficacy and locomotor function and Constipation improvement. Started Aug 2009; status: active, not recruiting.
02
Drugs
oxycodone + naloxoneoxycodone
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NL-OMON33756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33756.